Tetomilast: new promise for phosphodiesterase-4 inhibitors?

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2012-11-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2012.732065PMID 23043390
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review.

  2010cited by this paper
• Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

  2010cited by this paper
• Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL‐10‐deficient mice

  2008influential reference
• 5-Lipoxygenase-derived lipid mediators are not required for the development of NSAID-induced inflammatory bowel disease in IL-10-/- mice.

  2008cited by this paper
• Colonic expression of leukotriene‐pathway enzymes in inflammatory bowel diseases

  2007cited by this paper
• Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

  2007cited by this paper
• Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.

  2007cited by this paper
• A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis.

  2007influential reference
• Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease

  2007influential reference
• PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.

  2004cited by this paper
• Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee.

  2004cited by this paper
• Work losses related to inflammatory bowel disease in the United States: Results from the National Health Interview Survey

  2003cited by this paper
• Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591.

  1997cited by this paper
• Blockade of leukotriene production by a single oral dose of MK‐0591 in active ulcerative colitis

  1995cited by this paper
• Inflammatory Bowel Disease: Costs‐of-Illness

  1992cited by this paper
• Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis.

  1986cited by this paper
• [The long-term prognosis in ulcerative colitis. Results from a regional patient group in the county of Copenhagen].

  1985cited by this paper
• Alimentary tract andpancreas Prognosis inCrohn's disease -based onresults froma regional patient group fromthecounty ofCopenhagen

  1985cited by this paper
• Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents.

  1977cited by this paper
• ONTOGENETIC DEVELOPMENT OF A PHOSPHODIESTERASE ACTIVATOR AND THE MULTIPLE FORMS OF CYCLIC AMP PHOSPHODIESTERASE OF RAT BRAIN

  1974cited by this paper
• Separation of multiple molecular forms of cyclic adenosine-3',5'-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis.

  1972cited by this paper
• Digestive Diseases and Diabetes

  year unknowncited by this paper

• Design, Synthesis, and Evaluation of Selective PDE4 Inhibitors for the Therapy of Pulmonary Injury.

  2025cites this paper
• Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.

  2023cites this paper
• PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes

  2023cites this paper
• Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases

  2018cites this paper
• Small molecules with anti-inflammatory properties in clinical development.

  2016cites this paper
• 2,4-Disubstituted thiazoles as multitargated bioactive molecules

  2016cites this paper
• Inflammatory bowel diseases, chronic liver diseases and the lung

  2016cites this paper
• Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions.

  2016cites this paper
• In vivo effective dibenzo[b,d]furan-1-yl-thiazoles as novel PDE-4 inhibitors.

  2016cites this paper
• Discovery of Phosphodiesterase-4 Inhibitors: Serendipity and Rational Drug Design

  2014cites this paper
• Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?

  2014cites this paper
• Advances in targeting cyclic nucleotide phosphodiesterases

  2014cites this paper
• Phosphodiesterase-4 inhibitors: a review of current developments (2010 – 2012)

  2013cites this paper
• Phosphodiesterase-4 inhibitor therapy for lung diseases.

  2013cites this paper
• The COPD Pipeline XXIV

  2013cites this paper
• Synthesis of PDE IV inhibitors. First asymmetric synthesis of two of GlaxoSmithKline's highly potent Rolipram analogues.

  2013cites this paper
• Epigenetics: the fine-tuner in inflammatory bowel disease?

  2013cites this paper